Article
The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
International journal of cancer - 1 Jul 2016
Bogen Dominik, Brunner Clemens, Walder Diana, Ziegler Andrea, Abbasi Reza, Ladenstein Ruth L, Noguera Rosa, Martinsson Tommy, Amann Gabriele, Schilling Freimut H, Ussowicz Marek, Benesch Martin, Ambros Peter F, Ambros Inge M
Abstract excerpt
Amplification of MYCN is the signature genetic aberration of 20-25% of neuroblastoma and a stratifying marker associated with aggressive tumor behavior. The detection of heterogeneous MYCN amplification (hetMNA) poses a diagnostic dilemma due to the uncertainty of its relevance to tumor behavior. Here, we aimed to shed light on the genomic background which permits hetMNA in neuroblastoma and tied the occurrence...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.